TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06787144: A Phase 1 Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

Sponsor: Enliven Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 21 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$345,576

Rescue Site Savings

+$219,912

Unlock Full NCT06787144 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06787144 Rescue Dossier →